All In Biotech

Drug Trial Radar · NCT07390864

Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy

Intramyometrial Ergometrine Injection Versus Intramyometrial Carbetocin Injection to Decrease Blood Loss During and After Abdominal Myomectomy: A Randomized Clinical Trial

Last checked: Nov 20, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 18, 2026

Primary completion

Jul 30, 2026

Study completion Aug 30, 2026

Sponsor

Lead sponsor
Cairo UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kafrelsheikh University
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 25 years, up to 48 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids. The main questions it aims to answer are: Does intramyometrial ergometrine reduce intraoperative and postoperative blood loss during abdominal myomectomy? Does intramyometrial carbetocin reduce intraoperative and postoperative blood loss during abdominal myomectomy? Is there a difference between the two drugs in the need for blood transfusion and postoperative hemoglobin drop? Researchers will compare intramyometrial ergometrine injection with intramyometrial carbetocin injection to see which intervention is more effective in controlling surgical bleeding and improving surgical outcomes. Participants will: Undergo abdominal myomectomy for uterine fibroids Receive either intramyometrial ergometrine or intramyometrial carbetocin during surgery Be monitored for intraoperative blood loss, postoperative blood loss, hemoglobin changes, and need for blood transfusion

Conditions

  • Myoma;Uterus

Interventions

  • Methylergometrine (Intramyometrial Injection)Drug

    Methylergometrine maleate is administered as an intramyometrial injection diluted in normal saline and injected circumferentially around the myoma before uterine incision during abdominal myomectomy to induce sustained uterine contraction and reduce surgical blood loss.

  • Carbetocin (Intramyometrial Injection)Drug

    Carbetocin is administered as an intramyometrial injection diluted in normal saline and injected circumferentially around the myoma before uterine incision during abdominal myomectomy to promote sustained uterine contraction and reduce intraoperative and postoperative blood loss.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimated Intraoperative and Postoperative Blood LossTime frame: From the start of surgery until removal of the intraperitoneal drain (up to 48 hours postoperatively)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fayoum University

    Al Fayyum, Faiyum Governorate, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.